In agreement, a recent meta-analysis of 7 studies assessed the prognostic significance of WT1 mutations in adults with AML and reported that the remission rate of patients with WT1 mutations was inferior compared to that of patients with wild-type WT1 [33]. This evidence concerns the gene WT1 and acute myeloid leukemia.